Abstract
Recent exome-wide association studies have explored the role of coding variants in breast cancer risk, highlighting the role of rare variants in multiple genes including BRCA1, BRCA2, CHEK2, ATM and PALB2, as well as new susceptibility genes e.g., MAP3K1. These genes, however, explain a small proportion of the missing heritability of the disease. Much of the missing heritability likely lies in the non-coding genome. We evaluated the role of rare variants in the 5’ and 3’ untranslated regions (UTRs) of 18,676 genes, and 35,201 putative promoter regions, using whole-genome sequencing data from UK Biobank on 8,001 women with breast cancer and 92,534 women without breast cancer. Burden tests and SKAT-O tests were performed in UTR and promoter regions. For UTR regions of 35 putative breast cancer susceptibility genes, we additionally performed a meta-analysis with a large breast cancer case-control dataset. Associations for 8 regions at P<0.0001 were identified, including several with known roles in tumorigenesis. The strongest evidence of association was for variants in the 5’UTR of CDK5R1 (P=8.5×10−7). These results highlight the potential role of non-coding regulatory regions in breast cancer susceptibility.
Competing Interest Statement
JRBP and EJG are employees of Insmed Innovation UK and holds stock/stock options in Insmed Inc. JRBP also receives research funding from GSK and engages in paid consultancy for WW International Inc.
Funding Statement
The research has been conducted using the UK Biobank Resource under Application Number 28126. N.W. was supported by the International Alliance for Cancer Early Detection, an alliance between Cancer Research UK (C14478/A29329), Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London, and the University of Manchester. Quality control of the UK Biobank sequencing data has been funded by the Medical Research Council (unit programs: MC_UU_12015/2, MC_UU_00006/2). The BRIDGES project was supported by the European Union Horizon 2020 research and innovation programs BRIDGES (grant number, 634935 to P.D A.G.-N., A,M.D. and D.F.E) and B-CAST (633784 to M.K.S. M.K.S., P.D.P.P. and D.F.E.), the Wellcome Trust (v203477/Z/16/Z to S.H.T ad D.F.E), and Cancer Research UK (C1287/A16563). Details regarding funding of specific BRIDGES studies are provided in the Supplementary Material.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The organisations providing ethical approval for the contributing studies are summarised by Dorling et al, NEJM, https://www.nejm.org/doi/full/10.1056/NEJMoa1913948
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from UK Biobank are available through application to UK Biobank. Data from the Breast Cancer Association Consortium (BCAC) used in the present study are available upon reasonable request through the BCAC Data Access Coordinating Committee. All data produced in the present study are available upon reasonable request to the authors
